Enrico Martin

100 Chapter 5 References 1. Martin E, Muskens IS, Coert JH, Smith TR, Broekman MLD. Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature. Neuro-Oncology Pract . July 2018. doi:10.1093/nop/npy025 2. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg . 2009;249(6):1014-1022. doi:10.1097/ SLA.0b013e3181a77e9a 3. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer . 2006;107(5):1065-1074. doi:10.1002/cncr.22098 4. Stucky C-CH, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol . 2012;19(3):878-885. doi:10.1245/s10434-011-1978-7 5. Miao R, Wang H, Jacobson A , et al. Radiation -induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. Radiother Oncol . 2019;137:61-70. doi:10.1016/j.radonc.2019.03.015 6. Martin E, Coert JH, Flucke UE, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. Eur J Cancer . 2019;124:77-87. doi:10.1016/j. ejca.2019.10.014 7. Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): A long-term clinical study. Ann Oncol . 2008;19(2):390-394. doi:10.1093/annonc/ mdm450 8. Demehri S, Belzberg A, Blakeley J, Fayad LM. Conventional and functional MR imaging of peripheral ner ve sheath tumors: Initial experience. Am J Neuroradiol . 2014;35(8):1615-1620. doi:10.3174/ajnr.A3910 9. Matsumine A, Kusuzaki K, Nakamura T, et al. Differentiation between neurofibromas and malignant peripheral ner ve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol . 2009;135(7):891-900. doi:10.1007/s00432- 008-0523-y 10. Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer . 2016;56:77-84. doi:10.1016/j.ejca.2015.12.015 11. Bradford D, Kim A. Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options Oncol . 2015;16(3):328. doi:10.1007/s11864-015- 0328-6 12. Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol . 2014;4:324. doi:10.3389/fonc.2014.00324 13. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus s tandard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol . 2017;18(6):812-822. doi:10.1016/S1470-2045(17)30334-0 14. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma . 2017;2017:8685638. doi:10.1155/2017/8685638